IlluminOss Medical Announces Conditional FDA Approval for Clinical Trials of Groundbreaking Photodynamic Bone Stabilization System in the U.S.
Currently Recruiting Clinical Sites for Trial that May Offer Significant Advantages to Surgeons Treating Impending and Pathologic Fractures
East Providence, RI (November 18, 2014) – IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received conditional approval from the FDA to conduct a clinical trial for the treatments of impending and pathologic fractures in the humerus due to metastatic carcinoma. IlluminOss expects to begin enrolling clinical sites and initiate the trial shortly.
© 2019 Pappas Capital, LLC. ALL RIGHTS RESERVED.